These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 7215416)
21. Disopyramide phosphate: tissue uptake and relationship between drug concentrations in the plasma and myocardium of rats. Karim A; Kook C; Campion J; Doherty M Arch Int Pharmacodyn Ther; 1977 Aug; 228(2):222-36. PubMed ID: 921413 [TBL] [Abstract][Full Text] [Related]
22. Disopyramide pharmacokinetics in patients with acute myocardial infarction. Pentikäinen PJ; Huikuri H; Jounela AJ; Wilen G Eur J Clin Pharmacol; 1985; 28(1):45-51. PubMed ID: 3987785 [TBL] [Abstract][Full Text] [Related]
23. Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion. Lien E; Bakke OM Br J Clin Pharmacol; 1983 Jul; 16(1):71-6. PubMed ID: 6882625 [TBL] [Abstract][Full Text] [Related]
24. Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration. Haughey DB; Lima JJ Biopharm Drug Dispos; 1983; 4(2):103-12. PubMed ID: 6882879 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. Lintz W; Barth H; Osterloh G; Schmidt-Böthelt E Arzneimittelforschung; 1998 Sep; 48(9):889-99. PubMed ID: 9793614 [TBL] [Abstract][Full Text] [Related]
32. Disopyramide in acute myocardial infarction: problems with changing pharmacokinetics. Elliott HL; Thomson AH; Bryson SM Eur J Clin Pharmacol; 1986; 30(3):345-7. PubMed ID: 3732373 [TBL] [Abstract][Full Text] [Related]
33. [Pharmacokinetic and metabolic study of disopyramide in oral and intravenous administration]. De Graeve J; Kremers P; Gielen JE Therapie; 1977; 32(2):195-204. PubMed ID: 898127 [No Abstract] [Full Text] [Related]
34. Anti-arrhythmic and haemodynamic effects of intravenous and oral disopyramide in patients with ventricular arrhythmia. Hulting J; Rosenhamer G J Int Med Res; 1976; 4(1 Suppl):90-5. PubMed ID: 1026537 [No Abstract] [Full Text] [Related]
35. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide. Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575 [TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients. Aso R; Ohashi K; Katoh T; Ogata H Int J Clin Pharmacol Res; 2001; 21(3-4):137-46. PubMed ID: 12067143 [TBL] [Abstract][Full Text] [Related]
37. [Action of injected disopyramide on ventricular arrhythmias and atrioventricular conduction]. Vogel M; Desoutter P; Bellanger P; Motté G; Welti JJ Arch Mal Coeur Vaiss; 1976 Apr; 69(4):395-406. PubMed ID: 59581 [TBL] [Abstract][Full Text] [Related]
38. Kinetics of hemodynamic and electrocardiographic changes following intravenous disopyramide. Hulting J; Rosenhamer G Acta Med Scand; 1979; 205(5):417-23. PubMed ID: 443082 [TBL] [Abstract][Full Text] [Related]
39. Effect of oral disopyramide therapy on left ventricular function. Greene AC; Iskandrian AS; Hakki AH; Kane SA; Segal BL Chest; 1983 Mar; 83(3):480-4. PubMed ID: 6825481 [TBL] [Abstract][Full Text] [Related]